Literatur
- 1
Goldhirsch A, Wood W C, Gelber R D. et al .
Meeting highlights: updated international expert consensus on the primary therapy
of early breast cancer.
J Clin Oncol.
2003;
21
3357-3365
- 2
Kaufmann M, Minckwitz G von, Smith R. et al .
International expert panel on the use of primary (preoperative) systemic treatment
of operable breast cancer: review and recommendations.
J Clin Oncol.
2003;
21
2600-2608
- 3
Kaufmann M.
Preoperative (neoadjuvant) systemic treatment of breast cancer.
The Breast.
2005;
14 (Suppl 1)
29
- 4 Howell T.. On behalf of the ATAC Trialist' Group .The ATAC trial in postmenopausal
women with early breast cancer - updated efficacy results based on a median follow-up
of 5 years. SABCS 2004; 1
- 5
Howell A, Cuzick J, Baum M. et al .
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion
of 5 years' adjuvant treatment for breast cancer.
Lancet.
2005;
365
60-62
- 6
Thuerlimann B.
On behalf of the BIG 1-98 Collaborative Group. Letrozole versus tamoxifen as adjuvant
endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG
1-98: A prospective randomised double-blind phase III study.
The Breast.
2005;
14 (Suppl 1)
4
- 7
Coombes R C, Hall E, Gibson L J.
A randomized trial of exemestane after two to three years of tamoxifen therapy in
postmenopausal women with primary breast cancer.
N Engl J Med.
2004;
350
1081-1092
- 8 Coombes R C, Hall E, Snowdon C F, Bliss J M. The Intergroup Exemestane Study: a
randomized trial in postmenopausal patients with early breast cancer who remain disease-free
after two to three years of tamoxifen - updated survival analysis. SABCS 2004; 3
- 9 Jakesz R, Kaufmann M, Gnant M. et al. On behalf of the ABCSG and GABG .Benefits
of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole
after 2 years adjuvant tamoxifen: combined results from 3 123 women enrolled in the
ABCSG Trial 8 and the ARNO 95 Trial. SABCS 2004; 2
- 10
Kaufmann M, Jakesz R, Gnant M. et al .
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer
to anastrozole after 2 years adjuvant tamoxifen: combined results from 3 123 women
enrolled in the ABCSG Trial 8 and the ARNO Trial 95.
The Breast.
2005;
14 (Suppl 1)
81
- 11
Goss P E, Ingle J N, Martino S. et al .
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen
therapy for early-stage breast cancer.
N Engl J Med.
2003;
349
1793-1802
- 12 Goss P E, Ingle J N, Martino S. et al .Updated analysis of the NCIC CTG MA.17 randomized
placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal
women with early stage breast cancer. Proc ASCO 2004; 847: (abstract)
- 13
Henderson I C, Berry D A, Demetri G D. et al .
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin
dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast
cancer.
J Clin Oncol.
2003;
21
976-983
- 14 Mamounas E P, Bryant J, Lembersky B C. et al .Paclitaxel (T) following doxorubicin/cyclophosphamide
(AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP
B-28. Proc ASCO 2003; 12: (abstract)
- 15 Martin M, Pienkowski T, Mackey J. et al .TAC improves disease free survival and
overall survival over FAC in node positive early breast cancer patients, BCIRG 001:
55 months follow-up. SABCS 2003; 43: (abstract)
- 16 Roché H, Fumoleau P, Spielmann M T. et al .Five years analysis of the PACS 01 trial:
6 cycles of FEC100 vs. 3 cycles FEC100 followed by 3 cycles of docetaxel for the adjuvant
treatment of node positive breast cancer. SABCS 2004; 27: (abstract)
Prof. Dr. med. M. Kaufmann
Direktor der Klinik für Gynäkologie und Geburtshilfe der J. W. Goethe Universität
Theodor-Stern-Kai 7
60596 Frankfurt am Main
